Fast-Tracked Site Qualification for Clinical Trial Submission

QbD Group helped a biotech company complete 5 site qualification visits in just 3 weeks enabling a timely and compliant clinical trial submission.

Biotech company

Clinical

Medical Devices

Get in touch

QbD Group supported a dynamic life sciences company driving innovation in chronic disease management in preparing for a timely submission to the Competent Authority (CA) for a new clinical study.

Founded in 2021, the client focuses on developing technologies that improve the lives of patients with chronic degenerative conditions, particularly in the areas of musculoskeletal, connective tissue, and neurological disorders.

With tight regulatory timelines and five preselected sites to qualify, QbD ensured that all Site Qualification Visits (SQVs) were completed, documented, and fully compliant within just three weeks—helping the client stay on track with their clinical development goals and mission to improve and prolong patients’ quality of life worldwide.

Challenge

Accelerating site qualification to meet regulatory deadlines

To ensure an on-time submission to the Competent Authority (CA), the client needed to complete Site Qualification Visits (SQVs) for five preselected clinical trial sites within a three-week timeframe. This required fast coordination, complete documentation, and real-time follow-up from the Clinical Research Associate (CRA)—without compromising regulatory compliance or operational quality.

Approach

Orchestrating site activation under tight timelines

1. Initial site engagement

The CRA contacted each of the five preselected sites to share preliminary study details and gauge interest.
Upon signature of a Confidential Disclosure Agreement (CDA), each site received the study protocol synopsis.
CRA collected the availability of the Principal Investigators (PIs) and study coordinators to schedule SQVs within the three-week window.
Thanks to transparent communication about the tight timeline, all sites committed to rapid scheduling.

2. Pre-visit coordination

Essential documents such as GCP certificates, CVs, and signed site suitability forms were requested in advance.
The CRA followed up persistently via email and phone to collect the required materials before the visits.

3. On-site qualification visits

During each visit, the CRA evaluated:
- The site's ability to meet inclusion criteria and recruitment targets
- Local processes for informed consent and source data collection
- Access to EMRs, study coordinator support, and auxiliary departments (Pharmacy, Radiology)
Any outstanding documents were collected in person to complete each site’s file.

4. Reporting and sponsor communication

A comprehensive visit report was prepared for each site, outlining all observations and assessments.
All documents and findings were submitted to the sponsor for review.
Upon sponsor decision, CRA communicated site selection status via official letters.

Result

Achieving full compliance within three weeks

Through proactive planning, close collaboration, and hands-on coordination, QbD successfully completed and documented all five SQVs within the required three-week window. This allowed the client to submit its clinical study to the CA on time—meeting all compliance criteria and keeping the study launch on track.

Want to learn how to identify and manage risks during your clinical trial? Discover our expert strategies for minimizing uncertainty and ensuring trial success.

Read our practical guide on Clinical Trial Site Selection and Qualification

Clinical Trial Site Selection and Qualification: A Practical Guide

Learn the essential steps and key considerations for effective clinical trial site selection and qualification. Optimize timelines, budget, and compliance.

Read blog